Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -97.31% is 68% below its 5-year average of -58.08%, around the middle of its 5-year range (-177.15%–-21.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.43% above its 12-month average of -132.25%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -97.31%.
RETURN ON EQUITY (ROE)
-97.31%
RETURN ON EQUITY (ROE) AVG TTM
-132.25%
RETURN ON EQUITY (ROE) AVG 3Y
-70.27%
RETURN ON EQUITY (ROE) AVG 5Y
-58.08%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.43%
CURRENT VS 3Y AVG
-38.47%
CURRENT VS 5Y AVG
-67.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-131.62%
vs the sector median at left
SOPHiA GENETICS S.A.
Market Cap
$625.86M
Return on Equity (ROE)
-97.31%
TTM Avg
-132.25%
3Y Avg
-70.27%
5Y Avg
-58.08%
Market Cap
$616.72M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$629.87M
Return on Equity (ROE)
26.77%
TTM Avg
-106.09%
3Y Avg
-80.56%
5Y Avg
-51.63%
Market Cap
$637.69M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$635.18M
Return on Equity (ROE)
-471.98%
TTM Avg
-147.16%
3Y Avg
-120.43%
5Y Avg
-93.49%
Market Cap
$641.50M
Return on Equity (ROE)
-17.01%
TTM Avg
-22.91%
3Y Avg
-17.12%
5Y Avg
-14.58%
Market Cap
$601.66M
Return on Equity (ROE)
N/A
TTM Avg
-4.73%
3Y Avg
76.70%
5Y Avg
93.92%
Market Cap
$594.77M
Return on Equity (ROE)
-21.51%
TTM Avg
-20.05%
3Y Avg
-35.91%
5Y Avg
-26.18%
Market Cap
$655.05M
Return on Equity (ROE)
N/A
TTM Avg
385.53%
3Y Avg
385.53%
5Y Avg
385.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $625.86M | -97.31% | -132.25% | -70.27% | -58.08% |
| Climb Bio, Inc. (CLYM)vs › | $616.72M | -24.06% | -36.09% | -34.99% | -44.03% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $629.87M | 26.77% | -106.09% | -80.56% | -51.63% |
| Aura Biosciences, Inc. (AURA)vs › | $637.69M | -41.56% | -67.38% | -49.66% | -56.07% |
| Prime Medicine, Inc. (PRME)vs › | $635.18M | -471.98% | -147.16% | -120.43% | -93.49% |
| OmniAb, Inc. (OABI)vs › | $641.50M | -17.01% | -22.91% | -17.12% | -14.58% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $601.66M | N/A | -4.73% | 76.70% | 93.92% |
| AngioDynamics, Inc. (ANGO)vs › | $594.77M | -21.51% | -20.05% | -35.91% | -26.18% |
| Starling Oncology, Inc. (STLN)vs › | $655.05M | N/A | 385.53% | 385.53% | 385.53% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $659.73M | -44.63% | -42.69% | -38.09% | -55.51% |
ROE
-97.3%
ROA
-40.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -97.31% |
| 2026-03-31 | -177.15% |
| 2025-12-31 | -167.57% |
| 2025-09-30 | -123.55% |
| 2025-06-30 | -95.70% |
| 2025-03-31 | -77.29% |
| 2024-12-31 | -64.77% |
| 2024-09-30 | -62.90% |
| 2024-06-30 | -54.99% |
| 2024-03-31 | -55.19% |
| 2023-12-31 | -52.15% |
| 2023-09-30 | -43.48% |
| 2023-06-30 | -45.65% |
| 2023-03-31 | -44.16% |
| 2022-12-31 | -43.70% |
| 2022-09-30 | -46.07% |
| 2022-06-30 | -40.67% |
| 2022-03-31 | -34.34% |
| 2021-12-31 | -26.75% |
| 2021-09-30 | -21.67% |
| 2021-06-30 | -73.15% |
| 2021-03-31 | -50.53% |
| 2020-12-31 | -39.14% |
